NetworkSolutions.com - Original domain name registration and reservation services with variety of internet-related business offerings. Quick, dependable and reliable.
Employees: 11-50
Total raised: $60M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Scientia V... | scientiavc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.03.2014 | Series D | $60M | - |
Mentions in press and media 6
| Date | Title | Description |
| 26.03.2014 | Kolltan Pharmaceuticals Completes $60M Series D Financing | Kolltan Pharmaceuticals, a New Haven, CT-based biopharmaceutical company focused on the development of novel biologics targeting receptor tyrosine kinases, completed a $60m Series D financing. The round was led by a new investor, a Boston-b... |
| 24.03.2014 | Kolltan Pharma raises $60 million to initiate Phase 1 trials for cancer growth blockers | Among the company’s backers are Purdue Pharma, HBM BioCapital, Celtic Therapeutics Management, Tichenor Ventures and Osage University Partners. The biotechnology company was founded in 2007 in collaboration with the laboratory of Dr. Joseph... |
| 29.07.2013 | Yale spinoff licenses HER3 cancer drug from MedImmune, plans for Phase 1 trials in 2014 | Kolltan was established in 2007 in collaboration with the lab of Dr. Joseph Schlessinger at Yale School of Medicine to develop new biologic drugs that target receptor tyrosine kinases. Tyrosine kinases emerged more than a decade ago as clin... |
| 20.01.2010 | Kolltan Pharmaceuticals Closes $10M Series B Financing | Kolltan Pharmaceuticals, Inc., a New Haven, CT-based oncology therapeutics company, has raised $10m in investments and related payments from an affiliate of Celtic Therapeutics Holdings L.P. and Tichenor Ventures, LLC. The financing was led... |
| - | Yale spinoff licenses HER3 cancer drug from MedImmune, plans for Phase 1 trials in 2014 | A cancer drug startup spun out of the Yale School of Medicine has licensed the rights to develop and test a drug candidate from MedImmune designed to target a receptor that’s been connected to various cancers including breast, lung, ovary a... |
| - | Kolltan Pharma raises $60 million to initiate Phase 1 trials for cancer growth blockers | Yale spin-off Kolltan Pharmaceuticals has raised $60 million to advance its cancer treatment through clinical trials, according to a Form D filing with the Securities and Exchange Commission. The drug developer sees potential for the drug a... |